27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
ObjectiveTo review the application of artificial intelligence (AI) in the care of older adults with disabilities, identifying intervention type, target populations, and effects. 5 key findings →
Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundDementia disorders are affecting millions of people globally, characterized by memory loss, communication difficulties, and motor function decline. 1 key finding →
Participants: 64 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The machine learning model predicted MMSE scores with a root-mean-squared error (RMSE) of 2.43 in the BH test set. 4 key findings →
Participants: 945 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Copy number variation (CNV) of the amyloid-β precursor protein gene (APP) is a known cause of autosomal dominant Alzheimer disease (ADAD), but de novo genetic variants causing ADAD are rare. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Reimbursement decisions for new Alzheimer's disease (AD) treatments are informed by economic evaluations. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Fifty-two papers were finally retained after screening. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Most prevalent neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, Parkinson's disease and multiple sclerosis are heterogeneous in their clinical profiles and underlying pathophysiology, although they typically share the presence of cognitive impairment that worsens significantly during the course of the disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A digitally delivered intervention with minimal support appears acceptable and potentially engaging to older adults with higher and lower levels of cognitive performance. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These results suggest that the targeted methylation of APP via dCas9-Dnmt3a treatment can be a potential therapeutic strategy for AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
CogState and standard neuropsychological task scores were significantly lower for dementia participants than that of the nondementia groups (P < .05), with a single CogState test distinguishing control from MCI participants, but minimal differentiation existing between dementias using the CogState. 2 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source
In established dementia, administration of the CogState tasks appears sensitive to cognitive impairment in dementia. 1 key finding →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia poses a growing challenge for health services but remains stigmatized and under-recognized. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The majority of participants were women (63%), and large number of them used technological devices such as a smartphone (91%) or computer (81%). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dysfunction of the endolysosomal-autophagy network is emerging as an important pathogenic process in Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A reduced removal of dysfunctional mitochondria is common to aging and age-related neurodegenerative pathologies such as Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Most current Alzheimer's disease (AD) and mild cognitive disorders (MCI) studies use single data modality to make predictions such as AD stages. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To acquire larger samples for answering complex questions in neuroscience, researchers have increasingly turned to multi-site neuroimaging studies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this review, we focus on the potential role of the γ-aminobutyric acidergic (GABAergic) system in age-related episodic memory impairments in humans, with a particular focus on Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Every year, millions of brain magnetic resonance imaging (MRI) scans are acquired in hospitals across the world. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Brain MR images are the most suitable method for detecting chronic nerve diseases such as brain tumors, strokes, dementia, and multiple sclerosis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Overexpression of the amyloid precursor protein (APP) gene on chromosome 21 in Down syndrome (DS) has been linked to increased brain amyloid levels and early-onset Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
β-Amyloid precursor protein (APP) and its cleaved products are strongly implicated in Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Digital biomarkers are of growing interest in the field of Alzheimer's Disease (AD) research. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
With the global population rapidly aging, dementia has emerged as a major public health concern. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia poses a significant global health problem, necessitating early detection for effective intervention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 1,102 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →